We get this kind of incredulous statement often. The efforts of our little company appear superhuman and some people don’t believe we did it all ourselves. We started with 1:1 type II plants. Later, we played around with some type III lines (Ben Holmes’ Otto II and BaOx), but they play no role in our breeding program now. High content pure CBG plants didn’t exist in any form outside of GW Pharmaceuticals before us. We found a novel mutation and locked it in via targeted inbreeding. Our CBDV, CBCV, CBGV, and THCV lines are a combination of one OK propyl plant and thousands of seeds + inbreeding after finding trace amounts of propyl (you must have at least 2 independent propyl lines to make a CBD/V variety that will test legal post harvest on trimmed flowers (4 loci).
Yes, we all stand on the shoulders of those who came before us, but, honestly, the work we do to create our own unique lines from scratch is unlike anything in the cannabis space right now and hasn’t been seen since Hortapharm (Dave Watson) created the base varieties that were sold to GW Pharma. Unlike them, we are not just making a clone for production, but actually creating field-ready, stabilized varieties to make farmers (not pharma) successful.